Urinary epidermal growth factor in patients with gliomas: significance of the factor as a glial tumor marker

1993 ◽  
Vol 79 (3) ◽  
pp. 408-413 ◽  
Author(s):  
Hiroshi Kanno ◽  
Yasuhiro Chiba ◽  
Yoshikazu Kyuma ◽  
Akimune Hayashi ◽  
Hiroyuki Abe ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Tumor Marker ◽  
Glial Tumor ◽  
Total Removal ◽  
Glial Tumors ◽  
Group A ◽  
Epidermal Growth ◽  
Group B

✓ Epidermal growth factor (EGF) content in urine from patients with glial tumors was examined by radioimmunoassay techniques with labeled human EGF and its rabbit EGF polyclonal antibody. There was no cross-reaction with transforming growth factor-α, which has a common receptor with EGF. Forty glial tumors were divided into three groups according to the clinical stage: Samples from Group A patients were obtained before therapy and/or after biopsy; in these patients a large volume of tumor was apparent on computerized tomography (CT). Group B samples were obtained after gross total removal of the tumor and/or chemo- and radiation therapy; these patients showed a small volume of residual tumor on CT. Samples from Group C patients were obtained after gross tumor total removal and/or chemo- and radiation therapy; no tumor was detected on CT scans in these patients. Urinary EGF levels in Group A samples were statistically significantly higher than in samples from healthy individuals (p < 0.001), Group B patients (p < 0.10), and Group C patients (p < 0.02). In addition, high-grade glial tumors in Group A cases showed a significantly higher level of urinary EGF than low-grade tumors in Group A patients (p < 0.05), or patients with meningioma (p < 0.02), metastatic brain tumor (p < 0.05), and cerebral infarction (p < 0.001). Longitudinal changes of urinary EGF levels in glioma patients mostly synchronized with the clinical course and therapeutic interventions. Therefore, urinary EGF, as a glial tumor marker, may be of practical value for diagnosing a malignant glioma and evaluating for the efficacy of chemo- and radiation therapy.

scholarly journals A comparative study on topical recombinant human epidermal growth factor vs conventional betadine dressing in management of diabetic wounds

2020 ◽  
Vol 8 (1) ◽  
pp. 115
Author(s):  
Ajay Kundal ◽  
Manu Kohli ◽  
Sudershan Kapoor
Keyword(s):  
Wound Healing ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Significant Role ◽  
Cardio Vascular Disease ◽  
Group A ◽  
Epidermal Growth ◽  
Cardio Vascular ◽  
Group B ◽  
Diabetic Wounds

Background: Major complications of diabetes mellitus include cardio vascular disease, chronic kidney disease, diabetic foot ulcers and non-healing wounds. Lack of knowledge and awareness has led to worsening of wounds which can involve deeper tissues and bones also. If treated on time majority of patients can be prevented from undergoing major debilitating surgical procedures such as amputation of toes, foot etc.Methods: In this proposed study, 60 cases of diabetic wounds were studied for healing who were randomly allocated into two groups of 30 patients each. Group A included topical recombinant epidermal growth factor (EGF) application and group B included conventional Betadine dressing for wound healing.Results: Anaemia had a significant role in delaying wound healing in group B patients. Blood sugars had no significant role in delaying wound healing in this study as patients in group A had mean FBS more than group B and still the wound healing was observed better in group A patients. Topical recombinant EGF resulted in faster wound healing than conventional dressings in diabetic wounds. 90% wound healing rates were seen with topical EGF dressings in comparison to 36.67% in conventional betadine dressings. Signs of wound healing i.e., early granulation, decreased discharge, early wound closure were seen faster in group A. Moreover, all patients in group A showed healthy granulation tissue by the end of our study.Conclusions: We concluded that topical recombinant EGF resulted in faster and better wound healing than conventional betadine dressing.

scholarly journals Heparin-binding epidermal growth factor inhibits apoptosis in cisplatin-resistant pancreatic cancer cells via upregulation of EGFR and ERCC 1 expressions

2021 ◽  
Vol 18 (6) ◽  
pp. 1167-1171
Author(s):  
Lingyang Zhou ◽  
Yuming Wang ◽  
Shenghong Lan ◽  
Mingfu Hu ◽  
Lipeng Lu
Keyword(s):  
Pancreatic Cancer ◽  
Cell Proliferation ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Cancer Cells ◽  
Heparin Binding ◽  
Pancreatic Cancer Cells ◽  
Group A ◽  
Epidermal Growth ◽  
Group B

Purpose: To investigate the influence of heparin-binding epidermal growth factor (HB-EGF) on apoptosis in cisplatin-resistant pancreatic cancer cells, as well as its mechanism of action. Methods: Pancreatic cancer cisplatin-resistant cells (BXPC-3/CDDP) were transfected with HB-EGF small interfering RNA (siRNA). The cells were randomly assigned to four groups, namely, BXPC-3 group (group A), BXPC-3/CDDP group (group B), transfected group A (group Asi) and transfected group B (group Bsi). Cell proliferation was determined using MTT assay, and the levels of expression of HBEGF, epidermal growth factor receptor (EGFR) and excision repair cross-complementation group 1 (ERCC 1) were determined using Western blotting. The extent of apoptosis was determined by flow cytometry. Results: Cell proliferation was increased in group B, relative to group A, but was significantly decreased after transfection with HB-EGF siRNA (p < 0.05). The half-maximal inhibitory concentration (IC50) of group Bsi was reduced, relative to group Asi (p < 0.05). The expression of HB-EGF was significantly upregulated in group B, relative to group A (p < 0.05). In contrast, HB-EGF siRNA transfection of the cells significantly down-regulated HB-EGF expression (p < 0.05). Early apoptosis was significantly higher in group A than in groups B and Bsi. Higher levels of apoptosis were seen in group Bsi, relative to group B after inhibition of HB-EGF expression (p < 0.05). Conclusion: These results indicate that HB-EGF is resistant to cisplatin, and it inhibits apoptosis in pancreatic cancer cells via the upregulation of EGFR and ERCC 1 expressions.

Extent of bronchioloalveolar pattern and expression of the epidermal growth factor receptor in surgically resected lung adenocarcinomas

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 20065-20065
Author(s):  
I. J. Dahabreh ◽  
J. Janinis ◽  
E. A. Karagiani ◽  
A. Dountsis ◽  
K. Vasilikos ◽  
...  
Keyword(s):  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Growth Factor Receptor ◽  
Female Ratio ◽  
Histologic Subtype ◽  
Egfr Expression ◽  
Group A ◽  
Epidermal Growth ◽  
Group B

20065 Background: An increasing number of studies are exploring relations between the bronchioloalveolar differentiation of adenocarcinomas and clinical, radiological and molecular parameters. We investigated the potential relation between the extent of the bronchioloalveolar carcinoma (BAC) component of adenocarcinomas and the expression of the epidermal growth factor receptor (EGFR) protein. Methods: We retrospectively reviewed data from all patients who underwent surgery for lung cancer in our hospital between February 1, 2001 and May 31, 2005 (n = 366), and in whom pathologic analysis had revealed an adenocarcinoma histologic subtype. Paraffin embedded tissue samples were retrieved and re-examined. Samples exhibiting either a pure BAC histology or a mixed adenocarcinoma histology with a >50% BAC component (n = 46) were selected for EGFR expression analysis by immunohistochemical staining. Patient demographics, stage and tumor differentiation data were recorded. Histological analysis was carried out using the WHO 1999/2004 criteria for lung cancers. For EGFR expression evaluation, samples were assigned a score ranging from 0 to +3. Expression was considered positive when the score was +1 or higher. Statistical analysis was performed using the chi-square test. Results: Of the 46 tumor samples examined, 10 had a BAC component of 50–79% (group A), 18 had BAC component of 80–99% (group B) and 18 exhibited a pure BAC histology (group C). Male/female ratio was 61.3%/38.7%. Mean age at presentation was 61.6 years. Among group A, 4 patients were EGFR positive and 6 were EGFR negative. 16 group B patients were EGFR positive and 2 were EGFR negative. Similarly, 16 group C patients were EGFR positive and 2 were EGFR negative. This distribution suggests that EGFR is more often expressed with increasing BAC component (p = 0.0041). No correlation was observed between demographics and EGFR expression or the extent of BAC pattern. Conclusions: EGFR expression is related to the extent of the BAC component in adenocarcinomas, with statistical significance. Study of a larger number of patients and correlation of this finding with EGFR and Ras mutational status and responsiveness to therapy are warranted. No significant financial relationships to disclose.

scholarly journals The Effect of Epidermal Growth Factor on the Outcomes of Myringoplasty

2020 ◽  
Vol 3 (01) ◽  
pp. 23-26
Author(s):  
Kiran Ravindranath Bongale ◽  
Vikram Kemmannu Bhat ◽  
Mona Yadav
Keyword(s):  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Chronic Otitis Media ◽  
Pure Tone Audiometry ◽  
Tympanic Membrane Perforation ◽  
Controlled Study ◽  
Success Rates ◽  
Group A ◽  
Epidermal Growth ◽  
Group B

Abstract Introduction Chronic otitis media is a widespread disease of developing countries. The burden of the disease continues to be high and so is the demand for surgical myringoplasty. This pilot study aimed to compare in adults the outcomes of myringoplasty with and without the application of epidermal growth factor gel (EGF) with respect to the time taken for graft uptake, improvement of hearing, and complications. Materials and Methods This randomized controlled study was undertaken in a tertiary referral public hospital in a span of 2 years with a sample size of 60 patients. All of them underwent diagnostic nasal endoscopy, otoendoscopy, and pure tone audiometry and treated with conventional underlay myringoplasty using temporalis fascia (Group A—30 cases with EGF, Group B—30 controls without EGF). Patients were followed-up at 15, 30, 90 days postoperatively. Results The average time taken for closure of tympanic perforation and graft uptake by group A was lesser than group B. This difference was found to be statistically significant. Residual perforation at 1 month was commoner in group B as compared with group A. The final improvement of the hearing was the same in both the groups in the healed cases. Conclusion The EGF can be used to improve the outcomes of myringoplasty. It can hasten the closure of tympanic membrane perforation and increase the success rates of the surgery.

scholarly journals Treatment of tympanic membrane perforation with topical epidermal growth factor: progress towards clinical application

2021 ◽  
Vol 7 (5) ◽  
pp. 768
Author(s):  
Puneeth S. Nayak ◽  
Anil S. Harugop ◽  
Prashant H. Patil ◽  
Prasad T. V. R. K. ◽  
Lakshmi Goswami
Keyword(s):  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Tympanic Membrane ◽  
Tympanic Membrane Perforation ◽  
Cost Effective Treatment ◽  
Membrane Perforation ◽  
Group A ◽  
Epidermal Growth ◽  
Group B ◽  
Chemical Cautery

<p class="abstract"><strong>Background:</strong> Chronic otitis media is a widespread disease of developing countries, especially of the lower socio-economic group. Medical cost in hospitals associated with tympanoplasty for treating CSOM is very high. Our study investigates the efficacy of epidermal growth factor along with chemical cautery in healing of chronic tympanic membrane perforation on an outpatient department (OPD) basis. Hence providing a cheaper and cost effective treatment alternative to the patients.</p><p class="abstract"><strong>Methods:</strong> A total number of 70 patients with signs of COM attending ENT OPD were selected. The patients were randomly assigned into 2 groups each with a sample size of 35. Otoendoscopy and pure tone audiometry was performed. Group A was treated with EGF with chemical cautery and group B was treated with only chemical cautery. Both groups were followed up after 15 days, one month and second month of the procedure in ENT outpatient clinic.</p><p class="abstract"><strong>Results:</strong> The success rate of these non-healing perforation was found to be significantly higher in group A (29 [82.86%]) compared with group B (17 [65.71%]) with P value of 0.0070*.</p><p class="abstract"><strong>Conclusions: </strong>This study shows a statistically significant result with topical application of epidermal growth factor in small to medium non-healing central tympanic membrane perforation. Due to the promising result of epidermal growth factor, it could be considered as office myringoplasty.  </p>

scholarly journals Cetuximab associated dermal filler reaction

2019 ◽  
Vol 12 (8) ◽  
pp. e228882 ◽  
Author(s):  
Shivanshan Pathmanathan ◽  
Marcin Dzienis
Keyword(s):  
Epidermal Growth Factor Receptor ◽  
Radiation Therapy ◽  
Hyaluronic Acid ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Growth Factor Receptor ◽  
Dermal Filler ◽  
Dermal Fillers ◽  
Epidermal Growth ◽  
Receptor Inhibitor

A 52-year-old male patient with hyaluronic acid-based dermal fillers injected in his cheeks was diagnosed with glossotonsillary malignancy, and managed with concurrent cetuximab (epidermal growth factor receptor inhibitor) and radiation therapy. He developed significant inflammation around the dermal filler sites after first cycle of cetuximab which improved with dissolution of the dermal fillers with hyaluronidase. This suggests that cetuximab can lead to inflammation around the dermal filler sites, which can be treated with dissolution of the filler.

scholarly journals A comparative study of effect of epidermal growth factor on chronic leg ulcers with anti-septic dressing

2021 ◽  
Author(s):  
Mallikarjuna Reddy M. ◽  
Vijayabhaskarreddy Sirigireddy
Keyword(s):  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Chronic Wounds ◽  
Substantial Reduction ◽  
Test Group ◽  
Control Group ◽  
Medical College ◽  
Group A ◽  
Epidermal Growth ◽  
Healing Wounds

Background: Chronic wounds, particularly non-healing wounds, are one of the most prevalent surgical disorders that a surgeon may see. The characteristic of a chronic wound is that it does not heal despite daily dressings and costly local treatments. Aims of the study to investigate the healing effects of recombinant human epidermal growth factor (hEGF) on non-healing ulcers and to assess the effectiveness, acceptability, and safety of a new epidermal growth factor (EGF) wound dressing.Methods: On 60 patients with chronic non-healing ulcers, a randomized, prospective, and comparative research was conducted in the department of general surgery, SVS medical college and hospital, Mahbubnagar. These 60 patients were separated into two groups, each with fifteen patients. The EGF was applied to group A, whereas normal saline was given to group B.Results: The 60 patients who agreed to participate in the trial were separated into two groups (30 each) that were equal and comparable. Patients who received topical EGF 0.01% gel dressings were assigned to the trial, whereas those who received standard antiseptic wound dressing were assigned to the control group. Six of the fifteen patients in the test group were men, whereas eleven were males and four were females in the control group. When the two groups were compared, the test group had a substantial reduction in ulcer area compared to the control group (p<0.001)Conclusions: EGF is a superior alternative for treating chronic non-healing ulcers because of its cost effectiveness, availability, reduced hospital stay, and simplicity of administration.

Sign in / Sign up

Export Citation Format

Share Document